^
    12d
    Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Mayo Clinic | Initiation date: Nov 2025 --> Feb 2026
    Trial initiation date
    |
    Asparlas (calaspargase pegol-mknl)
    1m
    Efficacy and safety of DAPT regimen (dexamethasone, azacitidine, pegaspargase, tislelizumab) for NK/T cell lymphoma (ChiCTR2500109853)
    P2, N=50, Recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital
    New P2 trial
    |
    Tevimbra (tislelizumab-jsgr) • azacitidine • Oncaspar liquid (pegaspargase)
    1m
    Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Mayo Clinic
    New trial
    |
    Asparlas (calaspargase pegol-mknl)
    1m
    CASPER: Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, OHSU Knight Cancer Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Cotellic (cobimetinib) • Asparlas (calaspargase pegol-mknl)
    1m
    Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=53, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Apr 2028 --> Mar 2029 | Trial primary completion date: Apr 2028 --> Mar 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Truxima (rituximab-abbs) • mercaptopurine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Hemady (dexamethasone tablets) • Erwinase (erwinia asparaginase) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    2ms
    SPARK-ALL: Calaspargase Pegol in Adults With ALL (clinicaltrials.gov)
    P2/3, N=122, Active, not recruiting, Institut de Recherches Internationales Servier | Trial primary completion date: Feb 2026 --> Mar 2025
    Trial primary completion date
    |
    Asparlas (calaspargase pegol-mknl)
    2ms
    Asparagine Synthetase promoter hypermethylation is required, but not sufficient, for sensitivity to Asparlas in patient-derived models of hepatocellular carcinoma. (PubMed, Eur J Pharmacol)
    However, when a panel of patient derived xenograft models representing a range of pASNSmet levels was tested we found that high pASNSmet levels were required but not necessarily sufficient to confer sensitivity to treatment with Asparlas. Collectively, these results are in support of ASNS promoter hypermethylation as a targetable phenotype but indicate that pASNSmet alone is not a viable biomarker of this phenotype, and that significant advancements in our understanding of the underlying biology may be required before asparaginase-depleting therapy can be successfully implemented clinically in HCC.
    Journal
    |
    ASNS (Asparagine synthetase)
    |
    Asparlas (calaspargase pegol-mknl)
    2ms
    2087GCCC: Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) (clinicaltrials.gov)
    P1, N=27, Completed, University of Maryland, Baltimore | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> May 2025
    Trial completion • Trial completion date
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    TP53 mutation • IDH2 mutation
    |
    Venclexta (venetoclax) • Asparec (PEGylated recombinant Erwinia chrysantemi-derived L-asparaginase)
    2ms
    A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) (clinicaltrials.gov)
    P2, N=22, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • decitabine • Asparlas (calaspargase pegol-mknl)
    2ms
    Venetoclax Basket Trial for High Risk Hematologic Malignancies (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Andrew E. Place, MD | Recruiting --> Active, not recruiting | N=92 --> 13
    Enrollment closed • Enrollment change • Pan tumor
    |
    FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    KMT2A rearrangement • ABL1 fusion
    |
    Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane
    3ms
    CAALL-F01: A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents (clinicaltrials.gov)
    P3, N=2044, Active, not recruiting, Assistance Publique - Hôpitaux de Paris | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Mar 2027
    Enrollment closed • Trial completion date
    |
    Oncaspar liquid (pegaspargase)
    3ms
    Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study (clinicaltrials.gov)
    P=N/A, N=15, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Asparlas (calaspargase pegol-mknl)